Paper Details

  1. Home
  2. Paper Details

Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial.

Author: , BarrioJesús, BermejoFernando, CalvetXavier, CastroLuisa, CeballosDaniel, DomènechEugeni, EcharriAna, EsteveMaría, GisbertJavier P, GuardiolaJordi, HinojosaJoaquín, IglesiasEva, López-SanrománAntonio, Martín-ArranzMaría Dolores, Martínez-MontielPilar, Marín-JiménezIgnacio, Márquez-MosqueraLucía, MínguezMiguel, NosPilar, PonsVicente, RimolaJordi, TaxoneraCarlos, Vega RuizVicente, Vera-MendozaIsabel

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This phase 3 randomized controlled trial compared the efficacy of adalimumab (ADA) and azathioprine (AZA) in preventing postoperative recurrence of Crohn's disease (POR-CD) after ileocolonic resection. The study found that ADA did not demonstrate better efficacy than AZA in preventing POR-CD, although ADA was significantly better tolerated. This suggests that both ADA and AZA may be effective in preventing POR-CD, but that ADA may be a more suitable option for patients who experience adverse effects with AZA.
Paper Details　
Original Abstract of the Article :
BACKGROUND AND AIMS: Postoperative recurrence of Crohn's disease [POR-CD] is almost certain if no prophylaxis is administered. Evidence for optimal treatment is lacking. Our aim was to compare the efficacy of adalimumab [ADA] and azathioprine [AZA] in this setting. METHODS: We performed a phase 3, ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/ecco-jcc/jjx051

データ提供：米国国立医学図書館（NLM）

Comparing Treatments for Crohn's Disease Recurrence

Crohn's disease is a chronic inflammatory bowel disease that affects the gastrointestinal tract. When people with Crohn's disease undergo surgery, the disease often recurs. This study, much like a camel traversing a vast desert of research, aimed to find the best treatment to prevent this recurrence. The researchers compared the effectiveness of two medications, adalimumab (ADA) and azathioprine (AZA), in patients who had undergone surgery for Crohn's disease.

No Clear Winner in the Race to Prevent Crohn's Recurrence

The results showed that ADA and AZA were similar in their ability to prevent Crohn's disease recurrence. However, the researchers found that patients tolerated ADA better than AZA, meaning they were less likely to experience side effects and stop taking the medication. The study found that 4.4% of patients stopped taking ADA due to side effects, compared to 23.2% who stopped taking AZA. This is a significant difference, showing that ADA might be a more tolerable treatment option for Crohn's disease recurrence.

Navigating the Crohn's Treatment Landscape

These findings are important for patients with Crohn's disease who are considering surgery and need to choose a treatment to prevent recurrence. While both ADA and AZA are effective, the results suggest that ADA may be a more tolerable option for many patients. The researchers recommend that patients talk to their doctors about the benefits and risks of both medications to make an informed decision about their treatment plan.

Dr.Camel's Conclusion

This study is like a camel finding a refreshing oasis in the vast desert of Crohn's disease research. The findings suggest that adalimumab may be a better choice for many patients, offering a more comfortable journey through the treatment process. However, as with all things, it's important to remember that every camel – or patient – is different, and the best treatment plan will vary. Remember to consult your doctor for personalized advice.

Date :
  1. Date Completed 2018-06-25
  2. Date Revised 2022-03-18
Further Info :

Pubmed ID

28402454

DOI: Digital Object Identifier

10.1093/ecco-jcc/jjx051

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.